524715.BO - Sun Pharmaceutical Industries Limited

BSE - BSE Real Time Price. Currency in INR
576.30
+21.70 (+3.91%)
At close: 3:57PM IST
Stock chart is not supported by your current browser
Previous close554.60
Open551.00
Bid0.00 x 0
Ask0.00 x 0
Day's range548.00 - 580.00
52-week range507.15 - 604.50
Volume864,771
Avg. volume432,851
Market cap1.383T
BetaN/A
PE ratio (TTM)66.01
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Hold Sun Pharmaceutical Industries; target of Rs 597: Geojit
    Moneycontrol3 days ago

    Hold Sun Pharmaceutical Industries; target of Rs 597: Geojit

    Geojit recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 597 in its research report dated June 19, 2018.

  • Sun Pharma gains 3% post EIR for Halol facility; Morgan Stanley maintains underweight
    Moneycontrol11 days ago

    Sun Pharma gains 3% post EIR for Halol facility; Morgan Stanley maintains underweight

    The company has received the EIR (establishment inspection report) from the USFDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.

  • Reuters12 days ago

    Drugmaker Sun Pharma says Halol plant has gained U.S. clearance

    Supply restrictions imposed on India's largest drugmaker Sun Pharmaceutical Industries by U.S. regulators have been lifted, the company said on Tuesday, removing a major drag on its share price. Sun will now be able to resume shipments of drugs made at its Halol factory in western India, which contributed as much as 15 percent to its U.S. revenue in 2015. The restrictions on some drugs made at the site had been imposed after an inspection revealed quality control failures.

  • Buy Sun Pharmaceutical Industries; target of Rs 582: Khambatta Securities
    Moneycontrol13 days ago

    Buy Sun Pharmaceutical Industries; target of Rs 582: Khambatta Securities

    Khambatta Securities is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 582 in its research report dated May 30, 2018.

  • No re-inspection at Sun Pharma’s Halol unit sends stock soaring 9%
    Moneycontrol16 days ago

    No re-inspection at Sun Pharma’s Halol unit sends stock soaring 9%

    According to a report on CNBC-TV18, the company has received a voluntary action initiated (VAI) status for its Halol plant from US FDA.

  • Sun Pharma gains 8% post Q4 nos; CLSA, Macquarie upgrades rating
    Moneycontrol27 days ago

    Sun Pharma gains 8% post Q4 nos; CLSA, Macquarie upgrades rating

    Consolidated EBITDA margin stood at 24.1 percent in Q4FY18.

  • Reuterslast month

    Sun Pharma warns U.S. pricing pressure to hit 2019 profit

    Makers of generic drugs have seen poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the world's largest healthcare market. The warning compounds problems at Sun, which has been struggling to get clearance for its factories that are under U.S. supply bans due to quality control failures. It now plans to reduce its research spend on some generic drug projects that have become "unviable", Dilip Shanghvi, the company's founder and managing director, said on a conference call with analysts.

  • IANS India Private Limitedlast month

    Sun Pharma's Q4 consolidated net profit up 7%

    Mumbai, May 25 (IANS) Pharma major Sun Pharmaceutical Industries on Friday reported a rise of 6.96 per cent in its consolidated net profit for the quarter ended March 31, 2018. According to the company, its profit after tax for the quarter under review increased to Rs 1,308.96 crore from Rs 1,223.71 crore reported for the corresponding quarter of previous fiscal. Commenting on the financial performance, Dilip Shanghvi, Managing Director of the Company said: "Our Q4 performance is in-line with our guidance.

  • IANSlast month

    Sun Pharma's Q4 consolidated net profit up 7%

    Mumbai, May 25 (IANS) Pharma major Sun Pharmaceutical Industries on Friday reported a rise of 6.96 per cent in its consolidated net profit for the quarter ended March 31, 2018. According to the company, its profit after tax for the quarter under review increased to Rs 1,308.96 crore from Rs 1,223.71 crore reported for the corresponding quarter of previous fiscal. However, in terms of financial year, the pharma major's consolidated net profit declined by 68.96 per cent to Rs 2,161.55 crore from Rs 6,964.37 crore reported for 2016-17.

  • Sun Pharma gets USFDA nod for prostate cancer drug
    Moneycontrollast month

    Sun Pharma gets USFDA nod for prostate cancer drug

    In a regulatory filing, Sun Pharma and Churchill Pharmaceuticals, LLC said "one of Sun Pharma's wholly owned subsidiary companies has received approval from the US Food and Drug Administration (USFDA) for YONSA."

  • Sun Pharma receives USFDA approval for YONSA
    Moneycontrollast month

    Sun Pharma receives USFDA approval for YONSA

    Sun Pharmaceutical Industries and Churchill Pharmaceuticals, LLC today announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

  • Reuters4 months ago

    Sun Pharma quarterly profit plunges on weak U.S. sales

    Sun Pharma, along with other Indian pharmaceutical companies, has been battling increased competition in the generics market and greater pricing scrutiny in the United States. The drugmaker has also struggled as some of its products were banned from sale in the United States because the factories that made them did not meet U.S. quality standards. It was also hit by adjustments for U.S. tax reforms in the third quarter.

  • Reuters7 months ago

    Sun Pharma posts profit dive on U.S. pricing pressure

    REUTERS - India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other ...

  • Reuters10 months ago

    Sun Pharma reports first-quarter loss as generics business suffers

    India's largest drugmaker Sun Pharmaceutical Industries Ltd posted a surprise quarterly loss on Friday due to one-off legal costs and pressure over prices in its largest market, the United States, casting a shadow over its growth prospects. Sun is the latest maker of generic drugs to report poor sales as uncertainty grows in the global market for copycat drugs due to rising competition and pricing scrutiny in the United States. India's drugs industry, the world's fourth largest, has been hit particularly hard due also to challenges at home, where the government is tightening control over prices, and a nationwide tax reform has hit supplies.

  • IANS10 months ago

    Sun Pharma reports huge net loss for Q1

    Mumbai, Aug 11 (IANS) Sun Pharmaceutical Industries Ltd on Friday reported a huge net loss of Rs 1,291 crore for the first quarter (Q1) of fiscal 2017-18 on standalone basis, which is over eight times the net loss of Rs 152 crore incurred in the same period year ago. In a regulatory filing on the BSE, the leading drug maker said standalone revenue from operations for the quarter under review (Q1) was flat at Rs 1,803 crore as against Rs 1,800 crore in the like period year ago. Sequentially, revenue declined 11 per cent in Q1 from Rs 2,017 crore quarter ago when the net profit was Rs 95 crore.